TR201900542T4 - Ağrı ve/veya enflamasyon tedavisi için bileşimler. - Google Patents

Ağrı ve/veya enflamasyon tedavisi için bileşimler. Download PDF

Info

Publication number
TR201900542T4
TR201900542T4 TR2019/00542T TR201900542T TR201900542T4 TR 201900542 T4 TR201900542 T4 TR 201900542T4 TR 2019/00542 T TR2019/00542 T TR 2019/00542T TR 201900542 T TR201900542 T TR 201900542T TR 201900542 T4 TR201900542 T4 TR 201900542T4
Authority
TR
Turkey
Prior art keywords
inflammation
compositions
treating pain
pain
cosmetically
Prior art date
Application number
TR2019/00542T
Other languages
English (en)
Turkish (tr)
Inventor
Carreno Serraima Cristina
Van Den Nest Wim
Ferrer Montiel Antonio
Camprubi Robles Maria
FERNÁNDEZ CARNEADO Jimena
Ponsati Obiols Berta
Original Assignee
Bcn Peptides Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bcn Peptides Sa filed Critical Bcn Peptides Sa
Publication of TR201900542T4 publication Critical patent/TR201900542T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Materials Engineering (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
TR2019/00542T 2008-07-24 2009-07-24 Ağrı ve/veya enflamasyon tedavisi için bileşimler. TR201900542T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200802210A ES2356883B1 (es) 2008-07-24 2008-07-24 Composición para el tratamiento del dolor y/o la inflamación.

Publications (1)

Publication Number Publication Date
TR201900542T4 true TR201900542T4 (tr) 2019-02-21

Family

ID=41462205

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00542T TR201900542T4 (tr) 2008-07-24 2009-07-24 Ağrı ve/veya enflamasyon tedavisi için bileşimler.

Country Status (24)

Country Link
US (2) US20110206752A1 (https=)
EP (1) EP2318033B8 (https=)
JP (1) JP5920916B2 (https=)
KR (1) KR20110056491A (https=)
CN (1) CN102164610B (https=)
AR (1) AR072610A1 (https=)
AU (1) AU2009273471C1 (https=)
BR (1) BRPI0911743B1 (https=)
CA (1) CA2731880C (https=)
CY (1) CY1121125T1 (https=)
DK (1) DK2318033T3 (https=)
ES (2) ES2356883B1 (https=)
HR (1) HRP20190059T1 (https=)
HU (1) HUE042083T2 (https=)
IL (1) IL210810B (https=)
LT (1) LT2318033T (https=)
MX (1) MX2011000868A (https=)
PL (1) PL2318033T3 (https=)
PT (1) PT2318033T (https=)
RU (1) RU2515054C2 (https=)
SG (1) SG192548A1 (https=)
SI (1) SI2318033T1 (https=)
TR (1) TR201900542T4 (https=)
WO (1) WO2010009892A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961510A1 (fr) * 2010-06-17 2011-12-23 Oreal Utilisation comme agent de traitement de la transpiration humaine ; nouveaux derives d'acide amine ; compositions les contenant
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
CA2853791C (en) 2011-10-28 2017-10-24 Ruey J. Yu N-acyldipeptide derivatives and their uses
WO2013070808A1 (en) 2011-11-07 2013-05-16 Feng Tian Peptide-based compounds as inhibitors of neurotransmitter secretion
US9687669B2 (en) 2011-11-09 2017-06-27 John Stephan Wearable light therapy apparatus
JP2015508406A (ja) * 2012-01-03 2015-03-19 ルーイ・ジェイ・ユ Ｎ−アシルペプチド誘導体およびそれらの使用
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
CA2869599C (en) 2012-04-13 2021-07-27 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
DE102014007423A1 (de) * 2014-05-22 2015-11-26 Bitop Ag Zusammensetzung zur Behandlung des Auges
RU2580280C2 (ru) * 2014-07-08 2016-04-10 Общество с ограниченной ответственностью "НИТРОЗДРАВ" Композиция для местного применения для снижения или снятия болевого синдрома
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20190083809A1 (en) 2016-07-27 2019-03-21 Z2020, Llc Componentry and devices for light therapy delivery and methods related thereto
BR112019010888A2 (pt) * 2016-11-30 2019-11-12 Lubrizol Advanced Mat Inc uso de um composto, método cosmético, não terapêutico de tratamento e/ou de cuidado da pele, do cabelo, das unhas e/ou das membranas mucosas de um sujeito, e, composto
KR102293250B1 (ko) * 2017-09-18 2021-08-26 애니젠 주식회사 활성물질-헥사펩타이드 복합체 및 이를 포함하는 화장료 조성물
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
CN112165955A (zh) 2018-05-21 2021-01-01 益普生生物制药有限公司 抑制骨癌引起的异常性疼痛
ES3060502T3 (en) 2018-06-13 2026-03-26 Acraf Peptides having inhibitory activity on neuronal exocytosis
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
CA3132564A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Process for making stable bacterial extracts and their use as pharmaceuticals
EP3988092B1 (en) 2019-06-24 2026-01-28 Shenzhen Fangshengtai Medical Technology Co., Ltd. Oxovanadium complexes for use in the treatment of pain
CN116731111A (zh) * 2022-10-14 2023-09-12 深圳市维琪科技股份有限公司 合成肽及其组合物和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP0758900B1 (en) * 1994-05-09 2002-04-10 BINDER, William J. Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US7255866B2 (en) * 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
MX2007010674A (es) * 2005-03-03 2007-11-08 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de un oligopeptido.
CN101374860A (zh) * 2005-12-23 2009-02-25 技术转让合伙人公司 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
KR20090041066A (ko) * 2007-10-23 2009-04-28 성균관대학교산학협력단 신경전달물질 배출을 조절하는 합성 펩타이드

Also Published As

Publication number Publication date
BRPI0911743B1 (pt) 2021-11-16
PT2318033T (pt) 2019-01-24
HUE042083T2 (hu) 2019-06-28
RU2011105280A (ru) 2012-08-27
DK2318033T3 (en) 2019-02-04
EP2318033B8 (en) 2019-02-27
MX2011000868A (es) 2011-06-09
IL210810A0 (en) 2011-04-28
IL210810B (en) 2018-04-30
AU2009273471B2 (en) 2014-04-17
SI2318033T1 (sl) 2019-02-28
PL2318033T3 (pl) 2019-04-30
JP2011528678A (ja) 2011-11-24
ES2714357T3 (es) 2019-05-28
CA2731880C (en) 2016-12-13
BRPI0911743A2 (pt) 2015-07-07
WO2010009892A2 (en) 2010-01-28
WO2010009892A8 (en) 2011-02-24
AU2009273471A1 (en) 2010-01-28
AU2009273471C1 (en) 2014-08-21
US20110206752A1 (en) 2011-08-25
CA2731880A1 (en) 2010-01-28
CN102164610A (zh) 2011-08-24
AR072610A1 (es) 2010-09-08
HRP20190059T1 (hr) 2019-03-08
ES2356883A1 (es) 2011-04-14
EP2318033B1 (en) 2018-10-17
JP5920916B2 (ja) 2016-05-18
SG192548A1 (en) 2013-08-30
CY1121125T1 (el) 2019-12-11
CN102164610B (zh) 2014-04-09
EP2318033A2 (en) 2011-05-11
KR20110056491A (ko) 2011-05-30
RU2515054C2 (ru) 2014-05-10
LT2318033T (lt) 2019-02-11
WO2010009892A3 (en) 2010-05-14
ES2356883B1 (es) 2012-02-22
US20190184054A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
TR201900542T4 (tr) Ağrı ve/veya enflamasyon tedavisi için bileşimler.
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MX2022001952A (es) Compuestos de alquinil quinazolina.
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
ECSP088984A (es) Derivados de triazol ii
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
EA201000329A1 (ru) Циклические депсипептиды
EP2144590A4 (en) SKIN TREATMENT COMPOSITIONS AND METHODS
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
MX2010005012A (es) Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
EA201170344A1 (ru) Азаиндольные ингибиторы iap
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.